Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
-
New Prognostic System for Patients with Relapsed Follicular Lymphoma
May 2018Sureda A, et al. Cancer – A large-scale, long-term study of patients with relapsed follicular lymphoma (FL) has identified a new prognostic scoring system to assess risks of allogeneic hematopoietic cell transplantation (HCT). Results have shown that HCT can lead to a 5-year overall survival (OS) of 61% and a progression-free survival of 52%. -
Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT
May 2018Peggs KS and Moscowitz CH. Blood Advances – In a Point-Counterpoint feature in Blood Advances, two prominent hematologists, Drs. Karl S. Peggs and Craig H. Moscowitz, debate “Should all patients with Hodgkin lymphoma who relapse after autologous HCT be considered for allogeneic HCT?” -
Study Compares 5-Year Outcomes of Auto- vs. Allo-HCT in Patients with High-Risk FL
May 2018Smith SM, et al. Cancer – Patients with high-risk follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, can achieve a 5-year OS of 70% after autologous HCT. -
Study Shows Age Doesn't Affect Survival in HCT for NHL
April 2018Shah NN, et al. Blood Advances – Results from a study of 1,629 older adults show that older age per se should not make a patient ineligible for an allogeneic hematopoietic cell transplant (HCT) in non-Hodgkin lymphoma (NHL). -
Auto-HCT Improves Survival in Patients with FL and Early Therapy Failure
February 2018Casulo C, et al. Biol Blood Marrow Transplant – Patients with follicular lymphoma (FL) experiencing therapy failure within 2 years of frontline chemotherapy had better outcomes with an autologous HCT (auto-HCT) compared to a matched cohort of patients who did not undergo auto-HCT. -
Long-Term Outcomes Show Effectiveness of Reduced-Intensity HCT in MCL
February 2018Robinson SP, et al. Bone Marrow Transplant – Patients with mantle cell lymphoma (MCL) who have relapsed after an autologous transplant generally have a poor prognosis. Further treatment options include a second autologous transplant, an allogeneic transplant, or various alternative treatment strategies including novel agents. -
New Clinical Recommendations on the Role of HCT in Mature T Cell and NK/T Cell Lymphomas
December 2017Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant – New recommendations on the role of hematopoietic cell transplantation (HCT) for mature T cell and natural killer (NK)/T cell lymphomas outline clinical practice algorithms for 14 histological subtypes. -
Maintenance with Rituximab Prolongs Survival after Auto-HCT for Mantle Cell Lymphoma
November 2017Le Gouill S, et al. N Engl J Med – Rituximab maintenance therapy after autologous hematopoietic cell transplantation (HCT) significantly prolonged event-free survival, progression-free survival, and overall survival in patients with mantle cell lymphoma, according to a phase III randomized study of 299 patients <66 years old. -
Recent HCT Survival Improvements Reported for Hodgkin Lymphoma
June 2017Hegerova L, et al. Bone Marrow Transplant – This study of 72 patients with relapsed/refractory Hodgkin lymphoma (HL) has shown that allogeneic HCT outcomes have improved over time, primarily due to reductions in non-relapse mortality and decreased early relapse. -
Five-Year Disease-Free Survival Greater Than 80% with Auto-HCT for Hodgkin and DLBC Lymphoma
April 2017Myers R, et al. Biol Blood Marrow Transplant –In this multi-center study of 1,617 patients who survived for at least two years following autologous hematopoietic cell transplantation (auto-HCT) for Hodgkin lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL), 5-year disease-free survival (DFS) was >80%. -
Early Auto-HCT Improves Survival in High-Risk FL Patients
April 2017Casulo C, et al. Biol Blood Marrow Transplant – Patients with follicular lymphoma (FL) experiencing therapy failure within 2 years of frontline rituximab-based therapy have better outcomes when they undergo autologous hematopoietic cell transplantation (HCT) early (≤1 year from therapy failure), according to research results presented at the BMT Tandem Meetings. -
Report: Long-Term Follow Up Needed after HCT for CLL
January 2017van Gelder M, et al. Bone Marrow Transplant – Although allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for patients with chronic lymphocytic leukemia (CLL), a new study shows that HCT results in a higher mortality rate in transplant recipients compared to an age-, sex- and calendar year-matched general population. -
ASBMT Report: The Role of Allogeneic Transplant for CLL
November 2016Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant – Although allogeneic hematopoietic cell transplantation (HCT) is currently relegated to later stages of relapsed or refractory chronic lymphocytic leukemia (CLL), novel targeted therapies have altered clinical decision-making for the disease. -
MRD Accurately Predicts Survival in Patients with CLL
October 2016Kovacs G, et al. J Clin Oncol – Minimal residual disease (MRD) quantification results in improved progression-free survival (PFS) prediction in patients who achieve partial response (PR) and those who achieve complete remission (CR) after completion of chemotherapy or immunotherapy to treat chronic lymphocytic leukemia (CLL), according to combined results from two phase III studies. -
Haploidentical and Matched Related Donor HCT Result in Comparable Outcomes
June 2016Ghosh N, et al. J Clin Oncol – In this multi-center study of 987 adults with lymphoma undergoing HCT with post-transplant cyclophosphamide, outcomes were comparable between haploidentical (n=180) and matched sibling donors (MSD; n=807). -
HCT Yields Over 80% 3-Year Survival and Low Relapse in High-Risk FL Patients
May 2016Laport GG, et al. Biol Blood Marrow Transplant – Hematopoietic cell transplantation (HCT) using reduced-intensity conditioning with rituximab yields excellent survival in high-risk patients with follicular lymphoma (FL), according to results of a prospective phase II study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). -
Review: Advances in Allo-HCT Expand Use in Older Patients with NHL
May 2016Fenske TS, et al. Biol Blood Marrow Transplant – In this review, the authors present data supporting allogeneic HCT as a therapeutic option for patients with non-Hodgkin lymphoma (NHL) diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma focusing on patients over age 60. -
Prognostic Model Predicts HCT Outcomes in Patients with DLBCL
April 2016Fenske TS, et al. Br J Haematol – Researchers have developed a prognostic model to identify which patients with diffuse large B-cell lymphoma (DLBCL) who have failed a prior autologous transplant would best benefit from a subsequent allogeneic transplant. -
Haploidentical, Unrelated Donor HCT Outcomes Comparable in Lymphoma
March 2016Kanate AS, et al. Blood – Reduced-intensity HCT using haploidentical or matched unrelated donors (URD) yields comparable outcomes, according to a study of 917 adults transplanted for lymphoma. -
Allo- Better than Auto-HCT for Early Relapsed or Refractory Follicular Lymphoma
March 2016Lunning MA, et al. Brit J Haematol – An analysis of 44 patients with early relapsed or refractory follicular lymphoma (FL) shows a significant difference in 3-year event-free survival (EFS) between allogeneic and autologous transplantation (80% vs. 42%, respectively; p<0.015), but only in patients with previous remission duration of ≤12 months. -
Meta-Analysis: Outcomes of HCT in Hodgkin Lymphoma Have Improved Over Time
February 2016Rashidi A, et al. Bone Marrow Transplant – This meta-analysis encompassing 1,850 patients with Hodgkin lymphoma (HL) has found that hematopoietic cell transplantation (HCT) outcomes in HL have improved since 2000. -
HCT for Relapsed or Refractory Follicular Lymphoma Leads to 5-Year Survival of 52%
December 2015Sureda A, et al. ASH abstract oral presentation, December 2015 – Patients with relapsed/refractory follicular lymphoma (FL) can experience a 5-year progression-free survival (PFS) of 52%, according to the results of the largest FL study to date of 1,538 allogeneic hematopoietic cell transplant (HCT) recipients whose outcomes were reported to two major transplant registry databases. -
Comparable Outcomes in Unrelated Donor vs. Haploidentical HCT with Cyclophosphamide
December 2015Mussetti A, et al. ASH abstract oral presentation, December 2015 – Lower-intensity hematopoietic cell transplantation (HCT) using haploidentical donors and post-transplant cyclophosphamide for GVHD prophylaxis can achieve outcomes comparable to HLA-matched unrelated donor transplants, according to results of a retrospective study of 917 adults with Hodgkin or Non-Hodgkin lymphoma. -
Prognostic Model Identifies Relapsed DLBCL Patients Who Can Achieve Durable Progression-Free Survival After Allogeneic HCT
December 2015Fenske TS, et al. ASH abstract oral presentation, December 2015 – A new prognostic model identifies a subgroup of adults with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous transplant who can experience long-term progression-free survival following an allogeneic transplant. -
Survival 80% or Higher with Allogeneic HCT after Failed Autologous HCT for Lymphoma
December 2015Rezvani AR, et al. Bone Marrow Transplant – In a study of 47 patients with lymphoma who had failed prior autologous hematopoietic cell transplantation (HCT), 3-year overall survival was 81% after allogeneic HCT with a conditioning regimen using total lymphoid irradiation and antithymocyte globulin (TLI-ATG). -
Survival 65% or Higher in HCT for Progressive or Refractory Follicular Lymphoma
December 2015Yano S, et al. Bone Marrow Transplant – A multi-center retrospective study of reduced-intensity hematopoietic cell transplantation (HCT) in 46 adults with follicular lymphoma has shown that this therapy can result in a 5-year overall survival (OS) of 71.6%. -
Allogeneic HCT Better than Autologous HCT for Progression-Free Survival in Follicular Lymphoma
September 2015Klyuchnikov E, et al. Biol Blood Marrow Transplant – In adults with follicular lymphoma (FL), reduced-intensity allogeneic hematopoietic cell transplantation (HCT) yields better long-term survival compared to autologous HCT, according to results of a study of 518 rituximab-treated patients with FL transplanted between 2000 and 2012. -
Excellent Outcomes in Outpatient Autologous HCT for Patients with Myeloma or Lymphoma
July 2015Graff TM, et al. Bone Marrow Transplant – Researchers comparing outcomes of 230 patients with myeloma or lymphoma who underwent autologous hematopoietic cell transplantation (HCT) on an inpatient vs. outpatient basis within a single transplant program have found comparable outcomes in the two cohorts. -
No Clinical Benefit in Adding Radioimmunotherapy to BEAM Conditioning in Autologous HCT for Relapsed DLBCL
March 2013Vose JM, et al. J Clin Oncol — In patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (HCT), adding radioimmunotherapy to the standard BEAM conditioning regimen provides no clinical benefit, according to results from a randomized phase III clinical trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).